Wealth Enhancement Advisory Services, LLC Sage Therapeutics, Inc. Transaction History
Wealth Enhancement Advisory Services, LLC
- $55.6 Billion
- Q2 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 34,046 shares of SAGE stock, worth $295,519. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,046
Previous 43,638
21.98%
Holding current value
$295,519
Previous $346,000
10.4%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SAGE
# of Institutions
207Shares Held
50MCall Options Held
790KPut Options Held
440K-
Madison Avenue Partners, LP New York, NY6.08MShares$52.7 Million5.93% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$28.3 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT1.95MShares$16.9 Million0.07% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.92MShares$16.6 Million0.01% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...